The Hematologic Malignancies (HM) Program, which received ?Outstanding to Exceptional? merit in the 2010 CCSG renewal, was established in 1994 to translate basic scientific discoveries into novel therapeutics for patients with myeloid and lymphoid neoplasms. The Program has two scientific aims. They are to: 1) Develop a mechanisms-based understanding of the genetic, cellular, and biochemical processes regulating normal and malignant hematopoiesis, and 2) Translate basic scientific discoveries into more effective and manageable therapies. Thematic areas include transcriptional, translational, and epigenetic regulation of normal and malignant hematopoietic cells; signal transduction in normal and malignant hematopoietic cells; molecular therapeutics; hematopoietic stem cell biology and transplantation; and immune-based therapies. Program members are extensive users of CCSG-supported resources (e.g., Clinical Protocol and Data Management, Biostatistics Core, Clinical Cell and Vaccine Production Facility, Flow Cytometry and Cell Sorting Facility, and Human Immunology Core) and have extensive collaborations with other Abramson Cancer Center Programs including Cancer Control, Cancer Therapeutics, Immunobiology, Melanoma and Cutaneous Malignancies, Radiobiology and Imaging, and Pediatric Oncology. The Program is Co-Led by Dr. Edward Stadtmauer, an expert in clinical trials of novel therapeutics for hematologic malignancies and bone marrow transplantation, and Dr. Nancy Speck, an internationally known basic scientist working in the area of hematopoietic stem cells and leukemia. The Program's 21 members come from five departments (Medicine, Pediatrics, Genetics, Pathology and Laboratory Medicine, and Cell and Developmental Biology) in the Perelman School of Medicine. An innovative Hematologic Malignancies Translational Center of Excellence co-led by Dr. Stadtmauer has catalyzed an already successful Program by adding laboratory, tissue banking, and clinical research personnel resources as well as pilot grant funding. Prominent examples of Program advances include the demonstration by Dr. Blobel that the formation of chromatin loops directly activates transcription of globin genes, the demonstration by Dr. Tong that interaction of the cytokine signaling regulator Lnk with JAK2 is regulated by the 14-3-3 proteins, the reduction of graft versus host disease by CCR5 blockade, reported by a new member, Dr. Reshef and colleagues, and the application of Chimeric Antigen Receptor (CAR) modified T-cell therapy for CLL and B-cell ALL, led by Dr. Porter. Weekly seminars, collaborative grant submissions, weekly clinical working group meetings, and an annual research retreat organized by Drs. Speck and Stadtmauer facilitate member interactions. Currently, members have research funding totaling $6.7M (annual direct costs) of which $5M is peer-reviewed and $2.4M is from the NCI. During the project period, members published 358 cancer- relevant publications, of which 18% were intra-Programmatic, 20% were inter-Programmatic and 64% were multi-institutional.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
United States
Zip Code
Nicastri, Michael C; Rebecca, Vito W; Amaravadi, Ravi K et al. (2018) Dimeric quinacrines as chemical tools to identify PPT1, a new regulator of autophagy in cancer cells. Mol Cell Oncol 5:e1395504
Micallef, Ivana N; Stiff, Patrick J; Nademanee, Auayporn P et al. (2018) Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. Biol Blood Marrow Transplant 24:1187-1195
Medvec, Andrew R; Ecker, Christopher; Kong, Hong et al. (2018) Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium. Mol Ther Methods Clin Dev 8:65-74
Acosta, Jonuelle; Wang, Walter; Feldser, David M (2018) Off and back-on again: a tumor suppressor's tale. Oncogene 37:3058-3069
Crisalli, Lisa M; Hinkle, Joanne T; Walling, Christopher C et al. (2018) Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors. Biol Blood Marrow Transplant 24:1203-1208
Mazaleuskaya, Liudmila L; Salamatipour, Ashkan; Sarantopoulou, Dimitra et al. (2018) Analysis of HETEs in human whole blood by chiral UHPLC-ECAPCI/HRMS. J Lipid Res 59:564-575
Facompre, Nicole D; Harmeyer, Kayla M; Sahu, Varun et al. (2018) Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer. Oncotarget 9:8985-8998
Rosenfeld, Aaron M; Meng, Wenzhao; Chen, Dora Y et al. (2018) Computational Evaluation of B-Cell Clone Sizes in Bulk Populations. Front Immunol 9:1472
Shroff, Rachna T; Hendifar, Andrew; McWilliams, Robert R et al. (2018) Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precis Oncol 2018:
Fraietta, Joseph A; Lacey, Simon F; Orlando, Elena J et al. (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24:563-571

Showing the most recent 10 out of 1047 publications